erythromycin propionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1052 134-36-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • erythromycin estolate
  • erythromycin propionate
  • propiocine
  • propionyl erythromicin
  • propionylerythromycin
A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
  • Molecular weight: 790.00
  • Formula: C40H71NO14
  • CLOGP: 3
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 4
  • TPSA: 199.98
  • ALOGS: -3.63
  • ROTB: 10
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio fluctuation 216.72 125.42 33 421 2445 63486123
Bloody discharge 192.24 125.42 28 426 1523 63487045
Lyme disease 176.99 125.42 29 425 3420 63485148

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio fluctuation 216.20 165.30 33 384 3421 79740550
Bloody discharge 194.63 165.30 28 389 1925 79742046
Lyme disease 186.99 165.30 29 388 3321 79740650

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0028311 Macrolides
FDA PE N0000009982 Decreased Sebaceous Gland Activity
CHEBI has role CHEBI:23924 enzyme inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011500 Protein Synthesis Inhibitors
FDA EPC N0000175877 Macrolide
FDA EPC N0000175935 Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bile salt export pump Transporter IC50 5.39 CHEMBL
Bile salt export pump Transporter IC50 4.94 CHEMBL

External reference:

IDSource
D02525 KEGG_DRUG
3521-62-8 SECONDARY_CAS_RN
4017593 VANDF
4017594 VANDF
C0059564 UMLSCUI
CHEBI:48913 CHEBI
CHEBI:42355 CHEBI
CHEMBL2220427 ChEMBL_ID
CHEMBL2218877 ChEMBL_ID
C011807 MESH_SUPPLEMENTAL_RECORD_UI
HB75CIT999 UNII
71277 PUBCHEM_CID
DB00199 DRUGBANK_ID
4053 RXNORM
3636 MMSL
4675 MMSL
4676 MMSL
4799 MMSL
72164 MMSL
d00046 MMSL
002755 NDDF
002756 NDDF
005412 NDDF
10270000 SNOMEDCT_US
30427009 SNOMEDCT_US
372694001 SNOMEDCT_US
734518007 SNOMEDCT_US
D004918 MESH_DESCRIPTOR_UI
C0014806 UMLSCUI
39 INN_ID
12560 PUBCHEM_CID
D004917 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None